European Union Calls for Meridia Recall and Ban

Staff Writers

Add Your Comments

European Union (EU) medical experts have called for a recall of Meridia, saying that the weight-loss drug’s safety risks outweigh its benefits and that it is too dangerous for public use.

The recommendations by the European Medical Agency’s Committee for Medicinal Products for Human Use came as the FDA warned against use of the drug among patients with heart problems. Marketed as Meridia in the U.S., the sibutramine-based drug is sold in Europe as Reductil, Reduxade, and Zelium. The committee’s recommendations must be approved by the European Commission.

On January 21, the FDA said the drug’s heart risks require that it not be used in patients with a history of cardiovascular disease, such as congestive heart failure, stroke, and hypertension. However, the agency has thus far not indicated whether a Meridia recall will be issued. The consumer group Public Citizen filed a petition with the FDA late last year calling for a Meridia ban, citing additional information from a recent study that found the weight-loss drug may increase the risk of heart attacks, strokes and other cardiovascular problems

Do You Know about…

hair dye cancer lawsuits For Salon Professionals

Hair dye lawsuits are being pursued for salon professionals who were routinely exposed to hair dye chemicals and diagnosed with bladder cancer or breast cancer. See if you qualify for a hair dye cancer lawsuit settlement.

Learn More
SEE IF YOU QUALIFY FOR COMPENSATION
Hair-Dye-Cancer-Lawsuits
Hair-Dye-Cancer-Lawsuits

Do You Know About…

hair dye cancer lawsuits For Salon Professionals

Hair dye lawsuits are being pursued for salon professionals who were routinely exposed to hair dye chemicals and diagnosed with bladder cancer or breast cancer. See if you qualify for a hair dye cancer lawsuit settlement.

Learn More
SEE IF YOU QUALIFY FOR COMPENSATION

Meridia (sibutramine) was approved by the FDA in 1997 as a prescription-only weight loss supplement for obese patients with other risk factors such as diabetes, high cholesterol and controlled blood pressure.

In November 2009, the FDA announced that they were reviewing potential heart problems from Meridia after data suggested that side effects of the drug may cause users to suffer a higher number of cardiovascular events, such as heart attacks, strokes, resuscitated cardiac arrest or death.

The review was announced after FDA began examining data from a 10,000-patient study conducted in Europe known as the Sibutramine Cardiovascular Morbidity/Mortality Outcomes in Overweight or Obese Subjects at Risk of Cardiovascular Event (SCOUT). The latest recommendations came after further review of that data.

European medical experts were also consulting the SCOUT data when they came to the conclusion that the drug should be banned.

Tags: Cardiac Arrest, Heart Attack, Heart Failure, Meridia

More Lawsuit Stories

1 Comments

  1. Adrian

    Sibutramine was originally trialled as an antidepressant, it failed those trials, however it was noticed a few people mentioned appetite supression so it was trialled as a diet drug.
    Hey Presto, it passes with flying colours.
    Given that we now know its sideffects are increases in heart rate blood pressure etc, its not too much of a leap to guess that this is one of the side effects that caused it to fail as an antidepressent.
    So why on earth would they give a drug with these side effects to people who are overweight to begin with.
    They must have known what would happen if you give this drug to millions of people who are overweight.

Share Your Comments

This field is hidden when viewing the form
I authorize the above comments be posted on this page
Post Comment
Weekly Digest Opt-In

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

MORE TOP STORIES

Group of 7 BioZorb Injury Lawyers Appointed to Leadership Positions in Lawsuits Over Recalled Breast Tissue Marker
A federal judge has appointed the BioZorb lawyers to serve in various leadership positions during coordinated pretrial proceedings in the rapidly growing litigation, taking actions that benefit all plaintiffs pursuing a claim against Hologic.
MORE ABOUT: BIOZORB LAWSUIT
Women Can File Depo-Provera Brain Tumor Lawsuits Directly in MDL Order
A federal judge is expediting Depo-Provera brain tumor lawsuits towards resolution by permitting direct filing of new claims with the MDL court and appointing numerous plaintiffs’ attorneys to leadership roles.